ALBI and PALBI Scores and HCC Prognosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

645 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores.

To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection

NCT06934070

Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma (HCC) Prognosis

ACTIVE_NOT_RECRUITING

Patients With Obstructive Jaundice In Sohag University Hospital

NCT06456476

Obstructive Jaundice

RECRUITING

The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt

NCT05047146

Hepatocellular Carcinoma

COMPLETED

Hepatic Steatosis and Chronic Hepatitis B Virus

NCT05678582

Chronic Hepatitis

COMPLETED

Plasma MicroRNA for Prediction of Hepatocellular Carcinoma

NCT05449847

Hepatitis C

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma (HCC) Prognosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALBI

Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PALBI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion \> 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions \< 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels.

Exclusion Criteria

* Patients below 18 years old.
* Patients with pre-existing other malignancies.
* Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases.
* Patients with pre-existing haematologic disorders.
* Patients with proteinuria.
* Missed follow-up.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No